<span id="ldtbo"></span>

<track id="ldtbo"><div id="ldtbo"></div></track>
    <tbody id="ldtbo"></tbody>

      1. <tbody id="ldtbo"><nobr id="ldtbo"><address id="ldtbo"></address></nobr></tbody>
      2. <option id="ldtbo"><div id="ldtbo"></div></option>
      3. <track id="ldtbo"></track>

          <menuitem id="ldtbo"></menuitem><bdo id="ldtbo"></bdo>
        1. <tbody id="ldtbo"><div id="ldtbo"><td id="ldtbo"></td></div></tbody>

            <track id="ldtbo"></track>
            Image by Solera
            March 5, 2018 | By Solera

            Review Finds Switching From Reference Product To Biosimilar ‘Not Inherently Dangerous’

            A review in the journal Drugs found that moving to a biosimilar from a reference drug “is not inherently dangerous, and that patients, healthcare professionals, and the public should not assume that it is problematic.” Researchers looked at data from 90 studies, finding no differences in safety or efficacy after numerous switches between the biologic and the biosimilar.

            Click Here to view the original article at Regulatory Affairs Professional Society

            A smaller focus to make a much larger impact. Our goal is to deliver on every promise we make

            Our Mission

            Learn More